Bristol-Myers Squibb Company (BMY)
| Market Cap | 95.49B |
| Revenue (ttm) | 47.64B |
| Net Income (ttm) | 5.42B |
| Shares Out | 2.04B |
| EPS (ttm) | 2.67 |
| PE Ratio | 17.57 |
| Forward PE | 7.23 |
| Dividend | $2.48 (5.29%) |
| Ex-Dividend Date | Jul 3, 2025 |
| Volume | 7,024,134 |
| Open | 47.21 |
| Previous Close | 46.39 |
| Day's Range | 46.70 - 47.27 |
| 52-Week Range | 39.35 - 63.33 |
| Beta | 0.37 |
| Analysts | Hold |
| Price Target | 58.33 (+24.32%) |
| Earnings Date | Jul 31, 2025 |
About BMY
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for oncology, hematology, immunology, cardiovascular, neuroscience, and other areas. The company’s products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation and for the treatment of DVT/PE; Opdivo for various anti-cancer indications; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthrit... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 16 analysts, the average rating for BMY stock is "Hold." The 12-month stock price target is $58.33, which is an increase of 24.32% from the latest price.
News
Bristol-Myers Squibb: Strong Launch Portfolio Amid Market Reset
Initiate Bristol-Myers Squibb (BMY) with Buy and $57 PT, driven by high-momentum launches, robust pipeline, and underappreciated growth portfolio outperformance. BMY's $13bn+ annual FCF, strong balanc...
Bristol-Myers Squibb: You Might Wish You Bought More Now (Upgrade)
Bristol-Myers Squibb faces structural headwinds from legacy product losses, but its strong free cash flow and undervalued stock price provide downside protection. The recent $11B partnership with BioN...
U.S. Food and Drug Administration Approves Streamlined Patient Monitoring Requirements and Removal of REMS Programs within Bristol Myers Squibb's Cell Therapy Labels
PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #Abecma--U.S. FDA Approves Streamlined Patient Monitoring Requirements and Removal of REMS Programs within Bristol Myers Squibb's Cell Therapy Labels.
New vaccine panel meeting underway
CNBC's Angelica Peebles joins 'Squawk on the Street' to discuss the latest news on vaccines.
Cigna sues Bristol Myers over alleged monopoly for multiple myeloma drug Pomalyst
Cigna sued Bristol Myers on Tuesday, accusing the drugmaker of violating federal antitrust law by maintaining a monopoly over a blockbuster multiple myeloma drug sold under the brand name Pomalyst.
10 'Safer' Dividend Buys Of Barron's Better Bets Than T-Bills For June
Long-term bond yields continue to rise. But investors looking for income can still find plenty of attractive opportunities with dividend-paying stocks that have healthy yields. “23 stocks pay huge div...
I'm Buying Dividend Giants At Huge Discounts
Now is a great time to be an income and value investor, particularly in the energy and pharmaceutical spaces. I highlight 2 undervalued names that provide well-covered dividends with a strong growth o...
Bristol Myers Squibb Announces Dividend
PRINCETON, N.J.--(BUSINESS WIRE)--Bristol Myers Squibb Announces Dividend.
Bristol Myers Squibb Presents First Data from the Marginal Zone Lymphoma Cohort of the Transcend FL Trial Demonstrating Deep and Durable Responses with Breyanzi (lisocabtagene maraleucel)
PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #18ICML--BMS Presents First Data from the Marginal Zone Lymphoma Cohort of the Transcend FL Trial Demonstrating Deep and Durable Responses with Breyanzi.
Dividend Harvesting Portfolio Week 223: $22,300 Allocated, $2,310.77 In Projected Dividends
The Dividend Harvesting Portfolio hit a new all-time high, delivering a 26.95% return and $2,310.77 in forward annual dividend income. I continue to diversify across ETFs, REITs, CEFs, BDCs, and equit...
Bristol Myers Squibb Presents Data Across Targeted Protein Degradation Research Including CELMoD™ Agents and BCL6 Ligand-Directed Degrader at EHA 2025
PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #BMS--Bristol Myers Squibb Presents Data Across Targeted Protein Degradation Research Including CELMoD™ Agents and BCL6 Ligand-Directed Degrader at EHA 2025.
Bristol Myers Squibb to Report Results for Second Quarter 2025 on July 31, 2025
PRINCETON, N.J.--(BUSINESS WIRE)--Bristol Myers Squibb to Report Results for Second Quarter 2025 on July 31, 2025.
Bristol-Myers Squibb Company (BMY) Presents at Goldman Sachs 46th Annual Global Healthcare Conference (Transcript)
Bristol-Myers Squibb Company (NYSE:BMY) Goldman Sachs 46th Annual Global Healthcare Conference June 11, 2025 10:00 AM ET Company Participants Adam Lenkowsky - Executive VP & Chief Commercialization O...
Bristol Myers Squibb Presents Late-Breaking Data from Pivotal Phase 3 POETYK PsA-1 Trial Demonstrating Superiority of Sotyktu (deucravacitinib) Compared with Placebo in Adults with Psoriatic Arthritis
PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #EULAR--BMS Presents Late-Breaking Data from Pivotal Phase 3 POETYK PsA-1 Trial Demonstrating Superiority of Sotyktu.
Philochem AG Announces the Licensing of Worldwide Rights to OncoACP3, a novel Radiopharmaceutical Therapeutic and Diagnostic Agent targeting Prostate Cancer, to RayzeBio, a Bristol-Myers Squibb Company, for a potential value of up to $1.35bn plus royalties
Consideration composed of a $350m up-front payment and up to $1.0bn in development, regulatory and commercial milestones, along with mid-single to low double-digit royalties on Global Net Sales OTELFI...
5 Ideal 'Safe' Buys From June Fortune Return On Leadership Screen
Coincident to the June 5, 2025 annual launch of their Fortune 500, Fortune also partnered with Indiggo to measure Return On Leadership, called the ROL100. Arnold research focused on those 100 using YC...
Bristol-Myers And BioNTech Deal: Good For Both Parties, But One Is The Better Investment
Bristol-Myers Squibb is attractively valued, offers a 5%+ dividend yield, and benefits from a strong oncology pipeline after its BioNTech deal. The $11B BioNTech partnership gives BMY access to BNT327...
Healthy Returns: AstraZeneca, Pfizer, Gilead and other drugmakers release promising cancer drug data at ASCO
Drugmakers unveil cancer drug data at the ASCO annual meeting, while Amazon Pharmacy announces new features for caregivers, Medicare patients.
Bristol Myers CEO explains why he's spending billions on BioNTech deal
Bristol-Myers Squibb Co (NYSE: BMY) is inching up on Monday after announcing an $11 billion deal with BioNTech SE (Nasdaq: BNTX) aimed at transforming cancer treatment. The pharmaceutical behemoth ann...
Pharma may face more fundamentally negative headlines ahead, says Mizuho's Jared Holz
Jared Holz, Mizuho health care equity strategist, joins 'The Exchange' to discuss the impact of tariffs on pharmaceuticals and how to trade in the sector.
Bristol Myers Squibb CEO on $11B cancer drug deal with BioNTech
Christopher Boerner, CEO of Bristol Myers Squibb, said Monday that the company's $11 billion cancer drug partnership with BioNTech could be "the next new frontier in the treatment of cancer." The comp...
Bristol Myers CEO on Biontech deal: Next new frontier in treatment of cancer
Christopher Boerner, Bristol Myers CEO, joins 'Squawk on the Street' to discuss the company's recent partnership with Biontech, the cost of the deal and much more.
Bristol Myers makes $11 billion deal with BioNTech to join the cancer-drug race
Shares of BioNTech SE were soaring in early Monday trading, after Bristol Myers Squibb Co. made an $11.1 billion splash in the rapidly growing new cancer-drug game.
BioNTech Sets Cancer-Drug Deal With Bristol Myers Squibb
BioNTech and Bristol Myers Squibb have agreed to jointly develop and commercialize BioNTech's BNT327 cancer-drug candidate in a deal potentially worth more than $11 billion to the German drugmaker.
Bristol Myers to pay $1.5 billion upfront for BioNTech cancer drug partnership
U.S. drugmaker Bristol Myers Squibb announced on Monday a $1.5 billion upfront payment to partner with Germany's BioNTech , on an experimental cancer drug, in a deal that could eventually exceed $11 b...